Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach

por Pal, S.K., Gupta, R.K., Dosik, G., Figlin, R.A.
Publicado 2009

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

por Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Publicado 2012

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

por Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Publicado 2012

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

por Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Publicado 2017

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

por Yang, Y C, Lu, M L, Rao, J Y, Wallerand, H, Cai, L, Cao, W, Pantuck, A, Dalbagni, G, Reuter, V, Figlin, R A, Belldegrun, A, Cordon-Cardo, C, Zhang, Z F
Publicado 2006

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

por Hutson, T E, Bukowski, R M, Rini, B I, Gore, M E, Larkin, J M, Figlin, R A, Barrios, C H, Escudier, B, Lin, X, Fly, K, Martell, B, Matczak, E, Motzer, R J
Publicado 2014